Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04831281 · ClinicalTrials.gov registry record · Phase 2
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
A Phase 2 study, sponsored by LeonaBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04831281 is a Phase 2 study that was terminated before completion, run by LeonaBio. The registered enrollment target is 28 participants.
The verdict
NCT04831281, a Phase 2 study, was terminated before completion, sponsored by LeonaBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
Interventions
- DRUG Placebo
- DRUG ATH-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04831281
The ClinicalTrials.gov registry entry for NCT04831281 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04831281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04831281 about?
NCT04831281 is a clinical study titled "ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)". This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
What is the current status of trial NCT04831281?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2022-01-20. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT04831281?
The interventions under investigation include: Placebo (DRUG), ATH-1017 (DRUG).
Who is sponsoring clinical trial NCT04831281?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.